NewsRx

Search our medical news database

Finance

Campath continues steady sales progression

Published in Medical Letter on the CDC and FDA, March 7th, 2004

ILEX Oncology, Inc., (ILXO) reported that global net sales of Campath/Mabcampath (alemtuzumab) totaled $18.4 million in the fourth quarter of 2003.

That compares with sales of $11.7 million reported in the fourth quarter a year ago.

For the full year 2003, global net sales of Campath recorded by ILEX's marketing and distribution partner, Schering, AG, Germany (SHR) and its U.S. affiliate Berlex Laboratories, totaled $71.7 million, compared to $44.1 million in 2002.

"We were pleased to see our product-focused strategy pay off in 2003," said ILEX President and CEO Jeff Buchalter. "The growth outlook for Campath continues to be quite...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook